Advertisement

Related Videos

Amit Sanyal, MD: A Clinician’s Perspective

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Cost of Care
Health-Care Policy

The ASCO Post Staff

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Blase N. Polite, MD, MPP, of the University of Chicago Medical Center, discusses his belief that, in the next few years, we can bend the cancer drug cost curve and tame health-care costs if physicians, pharmaceutical companies, payers, and government come together and agree on the value of treatments that improve survival and quality of life.

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Advertisement

Advertisement




Oct
14
Today In Oncology
Alcohol and Cancer Risk: Is a Drop Too Much?
Surgical Resection With EGFR TKI Demonstrates Promising PFS in EGFR-Mutant NSCLC
In Extensive-Stage Small Cell Lung Cancer Novel Maintenance Regimen Boosts Overall Survival
EHA Publishes Guidelines for LBCL and Multiple Myeloma
Study Confirms It Is Never Too Late to See Survival Benefits From Quitting Smoking Even With Late-Stage Cancer
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo